Gastroenterology Search

Gastroenterology

Gastroenterology

Home News Diseases Conferences Special Reports

HEPATITIS B

Hepatitis B is transmitted through perinatal, percutaneous, sexual, and close person-to-person contact, ie by open cuts and sores.

Human hepatitis B virus belongs to the family of Hepadnaviridae of small, enveloped, primarily hepatotropic DNA viruses. The virus replicates in the host and assembles exclusively in the hepatocytes and virions are released non-cytopathically through the cellular secretory pathway.

Chronic hepatitis B is defined as a chronic necroinflammatory liver disease due to persistent hepatitis B virus infection.

Hepatitis D infection is found only in patients with hepatitis B as it requires the hepatitis B outer coat. It is transmitted through sexual and percutaneous (especially IV drug use) routes.

Hepatitis B and D both have an incubation period of 30-180 days.

Hepatitis%20b Treatment

Treatment

Liver Transplantation

Indicated in patients with end-stage liver disease (cirrhosis), hepatocellular carcinoma, and acute liver failure (ie caused by viruses, drugs and toxic agents)
- Considered in patients with expected survival of ≤1 year without transplantation or if quality of life is unsatisfactory due to the liver disease
Patients with HBV infection should be evaluated for liver transplantation despite antiviral therapy as development of liver failure cannot be predicted
- Combination therapy with hepatitis B immunoglobulin and nucleos(t)ide analogues helps prevent HBV recurrence in these patients undergoing liver transplantation
Recipient patients without anti-HBs should receive prophylaxis for HBV recurrence if transplanted liver is anti-HBc positive
HDV replication is not a contraindication for liver transplantation

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab